Hardik Patel, MD
Internal Medicine · Charleston, SCNPI 1558756676
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Angiodynamics, Inc. at 55.9% of the total. Reporting peaked in 2024 at $8,510 and has fallen 91.2% since, to $752 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $68.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Medtronic$2K
- AstraZeneca$2K
- Amgen$481
- Mallinckrodt Enterprises LLC$220
- Sequel Med Tech, LLC$210
- plus $2K from 31 others
What the payments were for
- Travel & lodging$1,46810%
- Food & beverage$4,83633%
- Education$1511%
- Other$8,19456%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $8,194 |
| Medtronic | 11 | $1,698 |
| AstraZeneca(2 entities) | 47 | $1,524 |
| Amgen(2 entities) | 28 | $481 |
| Mallinckrodt Enterprises LLC | 3 | $220 |
| Sequel Med Tech, LLC | 3 | $210 |
| Travere Therapeutics, Inc. | 12 | $206 |
| Otsuka America Pharmaceutical, Inc. | 10 | $191 |
| Vifor Pharma, Inc. | 11 | $184 |
| ANI Pharmaceuticals, Inc. | 5 | $169 |
| GSK | 7 | $134 |
| Insulet Corporation | 1 | $113 |
| Aurinia Pharma U.S., Inc. | 7 | $107 |
| Bayer | 6 | $103 |
| Fresenius USA Marketing, Inc. | 5 | $101 |
| Mallinckrodt Hospital Products Inc. | 5 | $97 |
| Kyowa Kirin, Inc. | 4 | $77 |
| Calliditas Therapeutics US Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $70 |
| Sanofi | 4 | $68 |
| Novo Nordisk | 3 | $68 |
| Akebia Therapeutics Inc | 4 | $63 |
| Merck | 4 | $62 |
| OPKO Pharmaceuticals, LLC | 3 | $55 |
| Scpharmaceuticals Inc. | 3 | $51 |
| Novartis | 3 | $46 |
| Lilly USA, LLC | 2 | $43 |
| Ardelyx, Inc. | 2 | $38 |
| W. L. Gore & Associates, Inc. | 2 | $37 |
| Bard Peripheral Vascular, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $30 |
| VBI Vaccine (delaware) Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Abbott | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $17 |
| Veloxis Pharmaceuticals, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$8,194
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,503
- TWIIST$186
- FARXIGA$125
- LOKELMA$125
- Omnipod$113
- ACTHAR$110
How this compares
$14,649 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 39 | $23,302 |
| FarxigaDapagliflozin Propanediol | 27 | $21,068 |
| Sevelamer Carbonate | 28 | $4,981 |
| Bumetanide | 24 | $394 |
| Calcitriol | 27 | $303 |
| Lisinopril | 40 | $242 |
| Carvedilol | 15 | $228 |
| Prednisone | 87 | $134 |
| Furosemide | 27 | $116 |
| Amlodipine Besylate | 14 | $99 |
| Ciprofloxacin Hcl | 23 | $89 |
| Losartan Potassium | 46 | $78 |
| Hydralazine Hcl | 11 | $43 |
| Hydrochlorothiazide | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $30 | $23,30239 claims |
| AstraZenecaFarxiga | $1,524 | $21,06827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- John CleekCharleston$136K
- Leonard AlsfeldCharleston$91K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
- Mithunan MaheswaranathanCharleston$14K
- Frances HughesCharleston$11K
- Molly McVeyCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.